SCHEMBL7248256

SCHEMBL7248256

N#Cc1ncc(OCc2ccccc2)c2ccccc12

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.50
KDM4E B2RXH2 1/20 0.50
POLB P06746 1/20 0.50
MAOB P27338 2/20 0.46
XDH P47989 2/20 0.42
MAPT P10636 2/20 0.41
L3MBTL1 Q9Y468 2/20 0.41
MAPK1 P28482 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
SGMS2 Q8NHU3 2/20 0.41
LTA4H P09960 1/20 0.41
MAPK14 Q16539 1/20 0.41
PLAU P00749 1/20 0.40
PLAT P00750 1/20 0.40
LMNA P02545 2/20 0.40
SQOR Q9Y6N5 1/20 0.40
NPC1 O15118 1/20 0.39
RAB9A P51151 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
HTR1A P08908 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24257809 0.78 MAPK1 (0.49) ALDH1A1KDM4EPOLBMAOBXDH
SCHEMBL25387499 0.77 XDH (0.47) MAOBXDHSGMS2LMNASQOR
SCHEMBL1921249 0.77 MAOB (0.53) ALDH1A1KDM4EPOLBMAOBXDH
SCHEMBL12985052 0.76 GCK (0.48) ALDH1A1MAOBXDHMAPTL3MBTL1
SCHEMBL20607927 0.76 GCK (0.46) MAOBXDHMAPK14SQORSMN1; SMN2
SCHEMBL18865570 0.76 PLAU (0.54) MAOBXDHSGMS2PLAUNPC1
SCHEMBL7238321 0.76 HTR1A (0.46) MAPTL3MBTL1MAPK1TDP1LTA4H
SCHEMBL26534330 0.76 L3MBTL1 (0.53) MAPTL3MBTL1MAPK1TDP1LTA4H
SCHEMBL10822615 0.74 MAOB (0.59) MAOBXDHMAPTL3MBTL1SGMS2
SCHEMBL4214379 0.74 LTA4H (0.58) ALDH1A1MAOBMAPTL3MBTL1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6528649-B2 Central nervous system disorders NEUROGEN CORPORATION 2003-03-04 US disclosed
US-20020019410-A1 Imidazoloisoquinolines NEUROGEN CORPORATION 2002-02-14 US disclosed
WO-2001092258-A1 IMIDAZOLOISOQUINOLINES NEUROGEN CORPORATION (US) 2001-12-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020019410-A1 Imidazoloisoquinolines GABRP, GABRA2, GABRA3 ALDH1A1 911/4885KDM4E 3160/4885POLB 3231/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.